- Home
- QXL vs TLPH Comparison
QXL vs TLPH Comparison
Compare QXL & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXL | TLPH |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.6M | 70.3M |
| IPO Year | 2015 | 2010 |
Fundamental Metrics
Financial Performance| Metric | QXL | TLPH |
|---|---|---|
| Price | $4.81 | $123.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 63.7K | ★ 301.1K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $26,941,000.00 | $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.05 | $0.50 |
| 52 Week High | $7.70 | $1.57 |
Technical Indicators
Market Signals| Indicator | QXL | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 44.24 |
| Support Level | $4.12 | $0.74 |
| Resistance Level | $5.06 | $1.48 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 77.27 | 24.36 |
Price Performance
Historical ComparisonAbout QXL Quantum X Labs Inc. Common Stock
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.